Status: Not yet recruiting
A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration
This clinical study is designed to demonstrate the equivalence of the two Investigational Products by comparing the efficacy, safety, tolerability and immunogenicity of RBS-001 and Eylea® in subjects with Neovascular age-related macular degeneration.
Participants needed: 434
Trial details
Phase: Phase 3Age: 50+Biological sex: AllType: InterventionalSponsor: Rophibio, Inc.Updated: Apr 6, 2025Locations: 7
Eligibility criteria
Age ≥ 50 years at screening [+5]
Individuals whose study eye lesion meets any of the following criteria [+13]